![[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US](https://i0.wp.com/ml-eu.globenewswire.com/media/ZTQzNjcwMWUtZTZmZi00MTQ2LTk4YzEtMDM3YWJiOTVmYTcxLTEwMTQyODItMjAyNS0wNC0xNC1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US")
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules…
FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples…
The Adecco Group: 2024 ANNUAL REPORT
ZURICH, March 12, 2025 /PRNewswire/ -- The Adecco Group 2024 Annual Report is…
The Adecco Group: Q4 & FULL YEAR 2024 RESULTS
Market share gains; strong cash generation; above target G&A savings driving resilient…
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12%…
Idorsia publishes an invitation to a bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will…
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER…
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera (ceftobiprole) in the United States
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16,…